Metelimumab (CAT-192) and fresolimumab (GC1008) are human monoclonal antibodies to transforming growth factor beta 1 (TGF-β1).
Lerdelimumab is a human monoclonal antibody to TGF beta 2,[REF] initially developed to combat fibrotic scarring that results from glaucoma drainage surgery [REF].